Role of levetiracetam in refractory seizures due to a rare progressive myoclonic epilepsy: Lafora body disease

Authors

Mubashira Hashmi, Aga Khan University
Feroza Saleem, Aga Khan UniversityFollow
Muhammad Shahid Mustafa, Aga Khan University
Mughis Sheerani, Aga Khan University
Zeeshan Ehtesham, Aga Khan University
Khurram Siddiqui

Document Type

Report

Department

Neurology

Abstract

Lafora disease is one of the rare, most fatal progressive myoclonic epilepsies reported. We present a case of a teenager with intractable seizures and progressive mental decline, diagnosed as Lafora body disease on axillary skin biopsy. He was admitted with status epilepticus with refractory myoclonic and generalised tonic clonic seizures. Despite on maximum doses of multiple antiepileptic drugs and infusions of propofol and midazolam, his seizures were refractory to all forms of medical therapy tried. Levetiracetam (LEV), a pyrrolidine derivative, was introduced; he showed a prompt response and was weaned off successfully from infusions of anticonvulsants and mechanical ventilation within 48 h of introduction of LEV, followed by an almost seizure-free status.

Comments

Rare disease

Publication (Name of Journal)

BMJ Case Reports

Recommended Citation

Hashmi, M., Saleem, F., Mustafa, M. S., Sheerani, M., Ehtesham, Z., Siddiqui, K. (2010). Role of levetiracetam in refractory seizures due to a rare progressive myoclonic epilepsy: Lafora body disease. BMJ Case Reports, 2010.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_neurol/170